Breaking News, Trials & Filings

ImmunoGen Begins ADC Trial

Targets EGFR in NSCLC, SCCHN and other solid tumors

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

ImmunoGen has begun a Phase I trial of its EGFR-targeting antibody-drug conjugate (ADC), IMGN289. IMGN289 will be evaluated in a multi-center trial designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and anticancer activity of the compound, administered weekly, in patients with non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck cancer (SCCHN), or other EGFR-positive solid tumors. Once its maximum tolerated dose is defined in the dose-fin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters